# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce two-signal model
- describe primary signal
- describe co-stimulatory signal
- discuss regulation of co-stimulatory signals
- introduce PD-1 and its role
- discuss PD-L1 overexpression in cancer
- describe PD-1 axis signaling inhibition
- highlight need for optimal therapy

## BRIEF SUMMARY OF THE INVENTION

- introduce combination treatment
- describe MEK inhibitor
- describe PD-1 axis binding antagonist
- outline methods for treating cancer
- outline use of PD-1 axis binding antagonist
- outline use of MEK inhibitor
- describe manufacturing process
- describe PD-1 axis binding antagonist for use
- describe MEK inhibitor for use
- outline methods for enhancing immune function
- describe types of cancer
- describe treatment results
- describe PD-1 axis binding antagonist types
- describe MEK inhibitor types

## DETAILED DESCRIPTION OF THE INVENTION

### I. General Techniques

- reference conventional methodologies
- cite laboratory manuals
- list molecular biology resources
- provide immunology references

### II. Definitions

- define PD-1 axis binding antagonist
- describe PD-1 binding antagonists
- specify PD-1 binding antagonist examples
- define PD-L1 binding antagonists
- describe PD-L1 binding antagonist examples
- define PD-L2 binding antagonists
- describe PD-L2 binding antagonist examples
- define dysfunction
- describe dysfunctional
- define anergy
- describe T cell anergy
- define exhaustion
- describe T cell exhaustion
- define enhancing T-cell function
- describe enhancing T-cell function examples
- define T cell dysfunctional disorder
- describe T cell dysfunctional disorder examples
- define tumor immunity
- describe tumor recognition
- define immunogenicity
- describe enhancing tumor immunogenicity
- define sustained response
- describe sustained response duration
- define antibody
- describe antibody composition
- define immunoglobulin
- describe IgM antibody structure
- describe IgA antibody structure
- describe IgG antibody structure
- define variable region
- describe variable domain
- define hypervariable regions
- describe framework regions
- define monoclonal antibody
- describe monoclonal antibody production
- define naked antibody
- define full-length antibody
- define Fc fragment
- describe effector functions of antibodies
- define FV fragment
- describe structure of FV fragment
- define single-chain Fv
- describe structure of single-chain Fv
- define functional fragments of antibodies
- give examples of antibody fragments
- define diabodies
- describe structure of diabodies
- define chimeric antibodies
- describe structure of chimeric antibodies
- define humanized antibodies
- describe structure of humanized antibodies
- define human antibodies
- describe methods for producing human antibodies
- define hypervariable regions
- describe structure of hypervariable regions
- define framework residues
- describe human consensus framework
- define VH subgroup III consensus framework
- define VL kappa I consensus framework
- define amino acid modification
- define affinity-matured antibodies
- describe methods for producing affinity-matured antibodies
- define specific binding
- describe characteristics of specific binding
- define immunoadhesins
- describe structure of immunoadhesins
- give examples of immunoadhesins
- describe production of immunoglobulin fusions
- give examples of immunoadhesins for combination therapy
- define soluble receptors
- define fusion protein
- define PD-1 oligopeptide
- define blocking antibody
- define agonist antibody
- define Fc region
- define Fc receptor
- define substantially reduced
- define substantially similar
- define carriers
- define package insert
- define treatment
- define delaying progression of a disease
- define effective amount
- define in conjunction with
- define complete response
- define partial response
- define stable disease
- define progressive disease
- define progression free survival
- define overall response rate
- define overall survival
- define chemotherapeutic agent
- list alkylating agents
- list aziridines
- list ethylenimines and methylamelamines
- list acetogenins
- list camptothecins
- list other chemotherapeutic agents
- list anti-metabolites
- list folic acid analogues
- list purine analogs
- list pyrimidine analogs
- list anti-adrenals
- list folic acid replenishers
- list other chemotherapeutic agents
- list taxoids
- list platinum analogs
- list vinca alkaloids
- list other chemotherapeutic agents
- define chemotherapeutic agents
- provide examples of chemotherapeutic agents
- define cytokine
- provide examples of cytokines
- define chemokine
- provide examples of chemokines
- define singular forms
- define "about"
- define alkyl
- provide examples of alkyl groups
- define alkenyl
- provide examples of alkenyl groups
- define alkynyl
- provide examples of alkynyl groups
- define carbocycle
- provide examples of carbocycles
- define aryl
- provide examples of aryl groups
- define heterocycle
- provide examples of heterocycles
- define heteroaryl
- provide examples of heteroaryls
- describe attachment of heterocycle or heteroaryl groups
- define halo
- define pharmaceutically acceptable salt
- provide examples of pharmaceutically acceptable salts
- describe preparation of pharmaceutically acceptable salts
- define solvate
- provide examples of solvates
- define hydrate
- describe aspects and variations of the invention

### III Methods

- introduce method for treating cancer
- administer PD-1 axis binding antagonist and MEK inhibitor
- treat various types of cancer
- specify cancer types
- treat cancer at different stages
- treat individuals with different conditions
- administer MEK inhibitor continuously
- administer MEK inhibitor intermittently
- administer MEK inhibitor before PD-1 axis binding antagonist
- administer MEK inhibitor simultaneously with PD-1 axis binding antagonist
- administer MEK inhibitor after PD-1 axis binding antagonist
- administer additional therapy
- specify additional therapy types
- administer radiation therapy
- administer surgery
- administer chemotherapy
- administer gene therapy
- administer DNA therapy
- administer viral therapy
- administer RNA therapy
- administer immunotherapy
- administer bone marrow transplantation
- administer nanotherapy
- administer monoclonal antibody therapy
- administer small molecule enzymatic inhibitor
- administer anti-metastatic agent
- administer side-effect limiting agents
- administer gamma irradiation
- administer therapy targeting PI3K/AKT/mTOR pathway
- administer HSP90 inhibitor
- administer tubulin inhibitor
- administer apoptosis inhibitor
- administer chemopreventative agent
- introduce PD-1 axis binding antagonists
- specify PD-1 axis binding antagonists
- introduce anti-PD-1 antibody
- specify anti-PD-1 antibody types
- introduce anti-PD-L1 antibody
- specify anti-PD-L1 antibody types
- describe antibody structure and function
- define anti-PD-L1 antibody
- specify heavy chain sequence
- specify light chain sequence
- describe constant region
- specify human constant region
- specify murine constant region
- describe effector function
- specify minimal effector function
- describe framework sequences
- specify heavy chain framework sequences
- specify light chain framework sequences
- describe another embodiment
- specify heavy chain sequence
- specify light chain sequence
- describe constant region
- specify human constant region
- specify murine constant region
- describe effector function
- specify minimal effector function
- describe framework sequences
- specify heavy chain framework sequences
- specify light chain framework sequences
- describe nucleic acid encoding antibody
- describe composition and administration
- introduce methods for treating cancer
- describe administering PD-1 pathway antagonist and MEK inhibitor
- specify MEK inhibitor compounds
- describe pharmaceutical composition or formulation
- define competitive inhibitor of MEK
- define selective inhibitor against activating KRAS mutation
- define allosteric inhibitor of MEK
- define selective inhibitor against activating BRAF mutation
- describe binding and inhibiting activity of MEK1 and/or MEK2
- list specific MEK inhibitor compounds
- define compound of formula (I)
- describe Group A: arylene optionally substituted
- describe Group A: X, R1, R2, R3, R4, R5, R6, and R7
- describe Group B: heteroarylene optionally substituted
- describe Group B: X, R1, R2, R3, R4, R5, R6, and R7
- describe Group C: A is
- describe Group C: R10, R10a, Y1, X, R1, R2, R3, R4, R5
- describe Group C: R6, and R7
- describe Group D (no content)
- summarize R8, R8', and R8"
- summarize R9
- summarize R30, R30', R31, R32, R33, R34, R34a, R35, R35a
- summarize R36, R36a, R37, R37a
- summarize cycloalkyl, heterocycloalkyl, aryl, heteroaryl
- summarize alkyl, alkenyl, alkynyl, haloalkyl, carboxy, carboxy ester
- define variables
- specify compound groups
- describe group A compounds
- describe group B compounds
- describe group C compounds
- describe group D compounds
- list specific compound examples
- reference synthesis methods
- define terms
- introduce alternative formula
- define MEK inhibitor compound
- specify variables Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R
- specify variables X1, X2, R11, R12, R13, R14, R15
- specify variables m, n, Y, Y'
- specify optional substituents for alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, ar
- specify R16, R17, R18, R19, R20, R21
- specify optional ring formation for R11, R12, R16, R17
- specify variations of MEK inhibitor compound
- specify specific compounds of formula (II-1-a) to (II-3-i)
- specify pharmaceutically acceptable salt or solvate
- reference WO 2008/024725 A1
- specify Examples 5-18, 20-102, 105-109, 111-118, 120-133, 136-
- specify IC50 of less than 10 μM
- specify IC50 of less than 5 μM
- reference page 62 in WO 2008/024725 A1
- conclude MEK inhibitor compound definition
- introduce MEK inhibitor compounds
- describe formula (II) compounds
- describe synthetic methods
- introduce formula (III) compounds
- define Z1, R1, R1'
- define Z2, Z3, R2, R3
- define R4, Y, W, W'
- define X1, R11', R11, R12, R13
- describe ring formation
- define R14, R15, X2, R7, R8, R9, R10
- conclude MEK inhibitor compounds
- define MEK inhibitor compounds
- specify variables for formula (III)
- provide variations of formula (III)
- describe compounds in Table 1
- reference WO 2009/085983 A1
- describe synthesis of formula (III) compounds
- introduce formula (IV) compounds
- specify variables for formula (IV)
- provide variations of formula (IV)
- list specific compounds of formula (IV)
- reference WO 03/077914 A1
- describe synthesis of formula (IV) compounds
- introduce formula (V) compounds
- specify variables for formula (V)
- provide variations of formula (V)
- describe compounds of formula (V)
- reference WO 03/077914 A1
- define MEK inhibitor compounds
- describe formula (V) variations
- describe synthesis methods
- define formula (VI) variables
- describe formula (VI) variations
- list specific formula (VI) compounds
- describe formula (VI) variations from WO 2007/096259 A1
- list specific formula (VI) compounds from WO 2007/096259 A1
- define formula (VII) variables
- describe formula (VII) variations
- describe formula (VI) variations from WO 2009/021887 A1
- list specific formula (VI) compounds from WO 2009/021887 A1
- list specific formula (VI) compounds
- describe additional MEK inhibitor compounds
- list specific additional MEK inhibitor compounds
- describe GDC-0973
- list additional specific MEK inhibitor compounds
- describe pharmaceutically acceptable salts or solvates

### IV Kits

- define kit composition
- specify kit instructions
- describe container options
- outline kit labeling

## EXAMPLES

- introduce examples of MEK inhibitor enhanced MHC I expression on tumor cell lines

### MEK Inhibitor Enhanced MHC I Expression on Tumor Cell Lines

- treat human tumor cell lines with MEK inhibitor
- assay surface expression of MHC-I on tumor cell lines
- compare MHC-I expression in MEKi and BRAFi treated cells
- demonstrate enhanced MHC-I expression in MEKi treated cells
- repeat experiment with mouse tumor cell lines
- demonstrate enhanced MHC-I expression in MEKi treated mouse cells
- assay MHC-I expression on human peripheral blood mononuclear cells
- demonstrate specificity of MEKi treatment to tumor cells

### Co-Stimulatory Signals Made T Cells Resistant to TCR Signaling Inactivation by MEK Inhibitor

- treat T cells with MEKi and T cell stimulation signals
- assay T cell proliferation
- demonstrate impaired T cell function with MEKi treatment
- co-stimulate T cells with anti-CD3 and anti-CD28
- demonstrate overcoming of MEKi inhibition with co-stimulation
- discuss potential mechanism of co-stimulation

### MEK Inhibitor Specifically Enhanced Maturation and Activation of Dendritic Cells

- treat monocyte-derived dendritic cells with MEKi and anti-CD40
- assay DC maturation and activation markers
- demonstrate enhanced DC maturation and activation with MEKi
- compare MEKi and BRAFi treatment effects on DCs
- demonstrate concentration-dependent effect of MEKi on DCs

### Co-Treatment with MEK Inhibitor and Anti-PD-L1 Antibodies Reduced Serum Levels of Cytokines that Promote Tumor Growth

- treat tumor-bearing animals with MEKi and anti-PD-L1 antibodies
- demonstrate reduced serum levels of immunosuppressive cytokines

### Example 5

- introduce MEK inhibition enhanced anti-tumor activity
- describe mouse model for colorectal tumors
- outline treatment groups and dosing regimens
- describe tumor growth monitoring and measurement
- calculate tumor volume and body weight changes
- analyze data using mixed models and R software
- plot results using Prism software
- define complete response and partial response
- calculate time to progression 5X
- analyze body weight changes using linear mixed-effects
- describe results of MEKi G-38963 treatment
- describe results of combination treatment with MEKi G-38963
- introduce MEKi GDC-0973 treatment
- describe dosing regimens for MEKi GDC-0973
- analyze results of MEKi GDC-0973 treatment
- describe results of combination treatment with MEKi GDC-0973
- introduce additional MEK inhibitors
- describe dosing regimens for MEK inhibitor G02443714
- analyze results of combination treatment with G02443714
- describe dosing regimens for MEK inhibitor G02442104
- analyze results of combination treatment with G02442104
- describe dosing regimens for MEK inhibitor G00039805
- analyze results of combination treatment with G00039805
- summarize results of all combination studies
- describe experimental design
- introduce Adventura Pro AV812 scale
- define body weight change equation
- describe data analysis using R
- introduce mixed modeling approach
- define tumor growth inhibition equation
- define complete response and partial response
- define time to progression 5X
- describe linear mixed-effects analysis
- summarize combination treatment results
- introduce MEK inhibition enhanced anti-tumor activity
- describe mouse models for melanoma tumors
- introduce treatment groups
- describe tumor growth and body weight changes
- summarize blockade of PD-L1 with anti-PD-L1 antibody
- describe treatment with MEKi G-38963
- summarize combination treatment results
- introduce MEK inhibitor increased activation of dendritic cells
- describe activation of dendritic cells
- summarize treatment with MEKi GDC-0973
- describe flow cytometry analysis
- introduce MEK assay
- describe MEK activity assay

